Phase II Trial of neoadjuvant chemotherapy with docetaxel, cisplatin and 5-FU for advanced esophageal cancer
- Conditions
- esophageal cancer
- Registration Number
- JPRN-UMIN000007408
- Lead Sponsor
- Second Department of Surgery, Wakayama Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Not provided
Different histological type from squamous cell carcinoma or adenocarcinoma Patient with allergic response to anticancer drugs (docetaxel, cisplatin, 5-FU) Active or uncontrolled infection Pregnancy (women of childbearing potential: refusal or inability to use effective means of contraception) Clinically significant heart disease Patients with a history of myocardial infarction within the previous three months Patients with uncontrolled diabetes mellitus or hypertension Patients with interstitial pneumonia or pulmonary fibrosis Patients who receive hemodialysis Presence of clinically apparent central nervous system metastases Patients with any other severe concurrent disease, which in the judgment of the investigator, would make the patient inappropriate for entry into this study Decision of unsuitableness by principal investigator or physician-in-charge
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method